nach oben

Erschienen in:

01.01.2005 | Article

The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes

verfasst von: G. D. Tan, B. A. Fielding, J. M. Currie, S. M. Humphreys, M. Désage, K. N. Frayn, M. Laville, H. Vidal, F. Karpe

Erschienen in: Diabetologia | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

We investigated the effects of rosiglitazone on NEFA and triglyceride metabolism in type 2 diabetes.

Methods

In a double-blind, placebo-controlled, cross-over study of rosiglitazone in diet-treated type 2 diabetic subjects, we measured arteriovenous differences and tissue blood flow in forearm muscle and subcutaneous abdominal adipose tissue, used stable isotope techniques, and analysed gene expression. Responses to a mixed meal containing [1,1,1-¹³C]tripalmitin were assessed.

Results

Rosiglitazone induced insulin sensitisation without altering fasting NEFA concentrations (−6.6%, p=0.16). Postprandial NEFA concentrations were lowered by rosiglitazone compared with placebo (−21%, p=0.04). Adipose tissue NEFA release was not decreased in the fasting state by rosiglitazone treatment (+24%, p=0.17) and was associated with an increased fasting hormone-sensitive lipase rate of action (+118%, p=0.01). Postprandial triglyceride concentrations were decreased by rosiglitazone treatment (−26%, p<0.01) despite unchanged fasting concentrations. Rosiglitazone did not change concentrations of triglyceride-rich lipoprotein remnants. Adipose tissue blood flow increased with rosiglitazone (+32%, p=0.03). Postprandial triglyceride [¹³C]palmitic acid concentrations were unchanged, whilst NEFA [¹³C]palmitic acid concentrations were decreased (p=0.04). In muscle, hexokinase II mRNA expression was increased by rosiglitazone (+166%, p=0.001) whilst the expression of genes involved in insulin signalling was unchanged. Adipose tissue expression of FABP4, LPL and FAT/CD36 was increased.

Conclusions/interpretation

Rosiglitazone decreases postprandial NEFA and triglyceride concentrations. This may represent decreased spillover of NEFAs from adipose tissue depots. Decreased delivery of NEFAs to the liver may lead to lowered postprandial triglyceride concentrations. Upregulation of hexokinase II expression in muscle may contribute to insulin sensitisation by rosiglitazone.

Auwerx J (1999) PPARγ, the ultimate thrifty gene. Diabetologia 42:1033–1049CrossRefPubMed

Way JM, Harrington WW, Brown KK et al (2001) Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269–1277CrossRefPubMed

Randle PJ, Garland PB, Hales CN, Newsholme EA (1963) The glucose-fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785–789CrossRefPubMed

Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3–10PubMed

Lebovitz HE, Banerji MA (2001) Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 56:265–294CrossRef

Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI (2000) Mechanism of troglitazone action in type 2 diabetes. Diabetes 49:827–831PubMed

Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA (2002) A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 8:1122–1128CrossRef

Tan GD, Debard C, Tiraby C et al (2003) A “futile cycle” induced by thiazolidinediones in human adipose tissue? Nat Med 9:811–812CrossRef

Finegood DT, McArthur MD, Kojwang D et al (2001) Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50:1021–1029PubMed

10.

Zhou YT, Grayburn P, Karim A et al (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 97:1784–1789

11.

Maggs DG, Buchanan TA, Burant CF et al (1998) Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:176–185PubMed

12.

Mayerson AB, Hundal RS, Dufour S et al (2002) The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797–802PubMed

13.

Hällsten K, Virtanen KA, Lönnqvist F et al (2002) Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51:3479–3485

14.

Nolan JJ, Jones NP, Patwardhan R, Deacon LF (2000) Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 17:287–294CrossRef

15.

King AB (2000) A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 23:557

16.

Freed MI, Ratner R, Marcovina SM et al (2002) Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90:947–952CrossRef

17.

Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI (2000) Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 43:278–284CrossRef

18.

Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN (2000) Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 17:40–47CrossRef

19.

Fonseca V, Rosenstock J, Patwardhan R, Salzman A (2000) Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283:1695–1702CrossRef

20.

Miyazaki Y, Mahankali A, Matsuda M et al (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710–719

21.

Bajaj M, Suraamornkul S, Pratipanawatr T et al (2003) Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52:1364–1370PubMed

22.

Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL (2000) Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose–response study. The Pioglitazone 001 Study Group. Diabetes Care 23:1605–1611

23.

Sakamoto J, Kimura H, Moriyama S et al (2000) Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278:704–711

24.

Vu-Dac N, Schoonjans K, Kosykh V et al (1995) Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96:741–750

25.

Karpe F (2002) Postprandial lipemia-effect of lipid-lowering drugs. Atheroscler Suppl 3:41–46CrossRef

26.

Ghazzi MN, Perez JE, Antonucci TK et al (1997) Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 46:433–439PubMed

27.

Antonucci T, Whitcomb R, McLain R, Lockwood D, Norris RM (1997) Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 20:188–193PubMed

28.

Sunayama S, Watanabe Y, Ohmura H et al (1999) Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis 146:187–193CrossRef

29.

Shirai K, Itoh Y, Sasaki H et al (1999) The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 46:35–41CrossRef

30.

Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM (1992) Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193–203

31.

Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H (1998) Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:1818–1820CrossRefPubMed

32.

Kobayashi J, Nagashima I, Hikita M et al (1999) Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol 47:433–439CrossRef

33.

Ranganathan S, Kern PA (1998) Thiazolidinediones inhibit lipoprotein lipase activity in adipocytes. J Biol Chem 273:26117–26122CrossRef

34.

Rieusset J, Auwerx J, Vidal H (1999) Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 265:265–271CrossRef

35.

McTernan PG, Harte AL, Anderson LA et al (2002) Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. Diabetes 51:1493–1498

36.

Frayn KN, Coppack SW (2001) Assessment of white adipose tissue metabolism by measurement of arteriovenous differences. Methods Mol Biol 155:269–279

37.

Frayn KN, Coppack SW, Humphreys SM, Whyte PL (1989) Metabolic characteristics of human adipose tissue in vivo. Clin Sci (Lond) 76:509–516

38.

Larsen OA, Lassen NA, Quaade F (1966) Blood flow through human adipose tissue determined with radioactive xenon. Acta Physiol Scand 66:337–345

39.

Rådegran G (1999) Limb and skeletal muscle blood flow measurements at rest and during exercise in human subjects. Proc Nutr Soc 58:887–898

40.

Evans K, Burdge GC, Wootton SA, Clark ML, Frayn KN (2002) Regulation of dietary fatty acid entrapment in subcutaneous adipose tissue and skeletal muscle. Diabetes 51:2684–2690PubMed

41.

Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A (2001) Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 42:17–21

42.

Auboeuf D, Vidal H (1997) The use of the reverse transcription-competitive polymerase chain reaction to investigate the in vivo regulation of gene expression in small tissue samples. Anal Biochem 245:141–148CrossRef

43.

Evans K, Clark ML, Frayn KN (1999) Effects of an oral and intravenous fat load on adipose tissue and forearm lipid metabolism. Am J Physiol 276:E241–E248

44.

Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191–2192PubMed

45.

Summers LK, Samra JS, Humphreys SM, Morris RJ, Frayn KN (1996) Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci (Lond) 91:679–683

46.

Jansson PA, Larsson A, Lönnroth PN (1998) Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus. Eur J Clin Invest 28:813–818CrossRef

47.

Issekutz B Jr, Bortz WM, Miller HI, Paul P (1967) Turnover rate of plasma FFA in humans and in dogs. Metabolism 16:1001–1009CrossRef

48.

Bonadonna RC, Groop LC, Zych K, Shank M, DeFronzo RA (1990) Dose-dependent effect of insulin on plasma free fatty acid turnover and oxidation in humans. Am J Physiol 259:E736–E750

49.

Miyazaki Y, Glass L, Triplitt C et al (2001) Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210–2219CrossRef

50.

Auboeuf D, Rieusset J, Fajas L et al (1997) Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46:1319–1327PubMed

51.

Guo Z, Hensrud DD, Johnson CM, Jensen MD (1999) Regional postprandial fatty acid metabolism in different obesity phenotypes. Diabetes 48:1586–1592.PubMed

52.

Kelly IE, Han TS, Walsh K, Lean ME (1999) Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288–293

53.

Virtanen KA, Hällsten K, Parkkola R et al (2003) Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 52:283–290

54.

Frayn KN, Coppack SW, Fielding BA, Humphreys SM (1995) Coordinated regulation of hormone-sensitive lipase and lipoprotein lipase in human adipose tissue in vivo: implications for the control of fat storage and fat mobilization. Adv Enzyme Regul 35:163–178CrossRef

55.

Tan KC, Tso AW, Tam SC, Pang RW, Lam KS (2002) Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with type 2 diabetes mellitus. Diabet Med 19:944–948CrossRef

56.

Reitsma JB, Castro Cabezas M, de Bruin TW, Erkelens DW (1994) Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 43:293–298CrossRef

57.

Damci T, Yalin S, Balci H et al (2004) Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care 27:1077–1080

58.

Laplante M, Sell H, MacNaul KL, Richard D, Berger JP, Deshaies Y (2003) PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes 52:291–299

59.

Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD (2004) Splanchnic lipolysis in human obesity. J Clin Invest 113:1582–1588CrossRef

60.

Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G (1995) Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95:158–166

61.

Malmstrom R, Packard CJ, Watson TD et al (1997) Metabolic basis of hypotriglyceridemic effects of insulin in normal men. Arterioscler Thromb Vasc Biol 17:1454–1464

62.

Lewis GF, Uffelman KD, Szeto LW, Steiner G (1993) Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes 42:833–842

63.

Avena R, Mitchell ME, Nylen ES, Curry KM, Sidawy AN (1998) Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg 28:1024–1031

64.

Karpe F, Fielding BA, Ilic V, Macdonald IA, Summers LK, Frayn KN (2002) Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes 51:2467–2473

65.

Campbell PJ, Carlson MG, Hill JO, Nurjhan N (1992) Regulation of free fatty acid metabolism by insulin in humans: role of lipolysis and reesterification. Am J Physiol 263:E1063–E1069

66.

Zierath JR, Ryder JW, Doebber T et al (1998) Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARγ agonist) action. Endocrinology 139:5034–5041CrossRef

67.

Kim YB, Ciaraldi TP, Kong A et al (2002) Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 51:443–448

68.

Meyer MM, Levin K, Grimmsmann T et al (2002) Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes. Diabetes 51:2691–2697

69.

Cline GW, Petersen KF, Krssak M et al (1999) Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341:240–246CrossRef

70.

Kelley DE, Mintun MA, Watkins SC et al (1996) The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 97:2705–2713

71.

Shepherd PR, Kahn BB (1999) Glucose transporters and insulin action—implications for insulin resistance and diabetes mellitus. N Engl J Med 341:248–257CrossRef

72.

Vestergaard H, Bjorbaek C, Hansen T, Larsen FS, Granner DK, Pedersen O (1995) Impaired activity and gene expression of hexokinase II in muscle from non-insulin-dependent diabetes mellitus patients. J Clin Invest 96:2639–2645

73.

Pendergrass M, Koval J, Vogt C et al (1998) Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes 47:387–394

74.

Kruszynska YT, Mulford MI, Baloga J, Yu JG, Olefsky JM (1998) Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes 47:1107–1113

75.

Ducluzeau PH, Perretti N, Laville M et al (2001) Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. Diabetes 50:1134–1142PubMed

76.

Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J (1997) Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARα and PPARγ activators. J Biol Chem 272:28210–28217CrossRef

Titel: The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes
verfasst von: G. D. Tan
B. A. Fielding
J. M. Currie
S. M. Humphreys
M. Désage
K. N. Frayn
M. Laville
H. Vidal
F. Karpe
Publikationsdatum: 01.01.2005
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 1/2005
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-004-1619-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

RAS-Blocker bei Hyperkaliämie möglichst nicht sofort absetzen

14.05.2024 Hyperkaliämie Nachrichten

Bei ausgeprägter Nierenfunktionsstörung steigen unter der Einnahme von Renin-Angiotensin-System(RAS)-Hemmstoffen nicht selten die Serumkaliumspiegel. Was in diesem Fall zu tun ist, erklärte Prof. Jürgen Floege beim diesjährigen Allgemeinmedizin-Update-Seminar.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Bildnachweise

Die Leitlinien für Ärztinnen und Ärzte, Ärztin führt eine Nierenultraschalluntersuchung durch/© Graphicroyalty / stock.adobe.com (Symbolbild mit Fotomodell), Schwangere misst Blutzucker/© MMPhotography / Getty Images / iStock (Symbolbild mit Fotomodell), Duktales Pankreaskarzinom/© Dörffel, Y., Wermke, W. / all rights reserved Springer Medizin Verlag GmbH, Füße einer adipösen Frau auf einem Laufband/© Idanupong / stock.adobe.com (Symbolbild mit Fotomodell)

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2005

In vitro generation of insulin-producing beta cells from adult exocrine pancreatic cells

Hormone-sensitive lipase is reduced in the adipose tissue of patients with type 2 diabetes mellitus: influence of IL-6 infusion

Disparity of autonomic control in type 2 diabetes mellitus

Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus

An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study